Key Takeaways
- • OSSTEC closed an $8 million funding round to support the first-in-human U.S. surgical cases of its ASCENT cementless, fixed-bearing partial knee system, according to a Business Wire release.
- • The round was led by EMBRYO Ventures, with participation from Neovate Capital, New Wave Ventures, Oxford Technology Innovation Finance and Empirical Ventures.
- • OSSTEC is developing 3D-printed cementless joint replacement implants, and the financing also supports its advance pipeline.
- • The company cites that around half of knee replacement patients are suitable for a partial knee procedure, pointing to the addressable market for the ASCENT system.
Summary
London-based OSSTEC, an orthopedic company developing 3D-printed cementless joint replacement implants, announced that it has closed $8 million to fund the first-in-human U.S. surgical cases of ASCENT, its cementless, fixed-bearing partial knee system, according to a Business Wire release dated November 3, 2026.
The round was led by EMBRYO Ventures, with participation from Neovate Capital, New Wave Ventures, Oxford Technology Innovation Finance and Empirical Ventures. The proceeds are directed toward the initial human implantation work in the United States and the launch of the ASCENT platform, as well as the company's broader advance pipeline.
The company points to a sizable addressable market, noting that around half of knee replacement patients are suitable for a partial knee procedure. Partial knee replacement, which resurfaces only the damaged compartment of the joint, is positioned as a less invasive alternative to a total knee replacement. The release frames the financing as a step toward commercial entry into the U.S. market for the cementless design.
The primary source available for this story is limited, and the full financial terms beyond the $8 million headline amount, such as valuation or round structure, were not disclosed in the material reviewed.
The round was led by EMBRYO Ventures, with participation from Neovate Capital, New Wave Ventures, Oxford Technology Innovation Finance and Empirical Ventures. The proceeds are directed toward the initial human implantation work in the United States and the launch of the ASCENT platform, as well as the company's broader advance pipeline.
The company points to a sizable addressable market, noting that around half of knee replacement patients are suitable for a partial knee procedure. Partial knee replacement, which resurfaces only the damaged compartment of the joint, is positioned as a less invasive alternative to a total knee replacement. The release frames the financing as a step toward commercial entry into the U.S. market for the cementless design.
The primary source available for this story is limited, and the full financial terms beyond the $8 million headline amount, such as valuation or round structure, were not disclosed in the material reviewed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.